Abstract
This review covers the design and development of B cell Toleragens, compounds developed for the treatment of antibody-mediated autoimmune diseases by antigen-specific suppression of autoantibodies. Multivalent forms of B cell epitopes consisting of oligonucleotides, peptides, proteins and polysaccharides are under various stages of development for treating systemic lupus nephritis, antiphospholipid syndrome, and organ rejection associated with xenotransplantation. The design and structure of the multivalent ligands are presented along with relevant biological results. Hapten-polymer conjugates that were used to elucidate the principles of B cell suppression are included. Multivalent ligands for T cell receptors and high affinity IgE receptors, which provide insight into immunoglobulin aggregation and signaling, are also briefly discussed.
Keywords: autoantibody, self-antigen, Immunotherapy, b cell receptors (bcr), igm, b cell suppression, epitopes, oligonucleotide, xenotransplantation
Current Medicinal Chemistry
Title: Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Volume: 12 Issue: 16
Author(s): David S. Jones
Affiliation:
Keywords: autoantibody, self-antigen, Immunotherapy, b cell receptors (bcr), igm, b cell suppression, epitopes, oligonucleotide, xenotransplantation
Abstract: This review covers the design and development of B cell Toleragens, compounds developed for the treatment of antibody-mediated autoimmune diseases by antigen-specific suppression of autoantibodies. Multivalent forms of B cell epitopes consisting of oligonucleotides, peptides, proteins and polysaccharides are under various stages of development for treating systemic lupus nephritis, antiphospholipid syndrome, and organ rejection associated with xenotransplantation. The design and structure of the multivalent ligands are presented along with relevant biological results. Hapten-polymer conjugates that were used to elucidate the principles of B cell suppression are included. Multivalent ligands for T cell receptors and high affinity IgE receptors, which provide insight into immunoglobulin aggregation and signaling, are also briefly discussed.
Export Options
About this article
Cite this article as:
Jones S. David, Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases, Current Medicinal Chemistry 2005; 12 (16) . https://dx.doi.org/10.2174/0929867054546681
DOI https://dx.doi.org/10.2174/0929867054546681 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Molecular Characterization of the T Cell Repertoire Using Immuno-scope Analysis and its Possible Implementation in Clinical Practice
Current Molecular Medicine Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA
Protein & Peptide Letters Regulatory T Cells in Severe Drug Eruptions
Current Immunology Reviews (Discontinued) Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism Deciphering the Antibodyome - Peptide Arrays for Serum Antibody Biomarker Diagnostics
Current Proteomics